214 related articles for article (PubMed ID: 32525770)
1. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
2. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
4. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
5. Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.
Boukalova S; Hubackova S; Milosevic M; Ezrova Z; Neuzil J; Rohlena J
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165759. PubMed ID: 32151633
[TBL] [Abstract][Full Text] [Related]
6. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
7. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
Fitzpatrick LR; Deml L; Hofmann C; Small JS; Groeppel M; Hamm S; Lemstra S; Leban J; Ammendola A
Inflamm Bowel Dis; 2010 Oct; 16(10):1763-77. PubMed ID: 20310011
[TBL] [Abstract][Full Text] [Related]
8. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
10. Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Dorasamy MS; Choudhary B; Nellore K; Subramanya H; Wong PF
J Cancer; 2017; 8(15):3086-3098. PubMed ID: 28928900
[TBL] [Abstract][Full Text] [Related]
11. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
12. Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
Ishikawa C; Mori N
Eur J Haematol; 2024 Jul; 113(1):99-109. PubMed ID: 38558052
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia.
Zhang Y; Luo T; Ding X; Chang Y; Liu C; Zhang Y; Hao S; Yin Q; Jiang B
Biochem Biophys Res Commun; 2021 Apr; 547():162-168. PubMed ID: 33610916
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
16. Dihydroorotate dehydrogenase depletion hampers mitochondrial function and osteogenic differentiation in osteoblasts.
Fang J; Yamaza H; Uchiumi T; Hoshino Y; Masuda K; Hirofuji Y; Wagener FA; Kang D; Nonaka K
Eur J Oral Sci; 2016 Jun; 124(3):241-5. PubMed ID: 27086500
[TBL] [Abstract][Full Text] [Related]
17. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
[TBL] [Abstract][Full Text] [Related]
18. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Mao C; Liu X; Zhang Y; Lei G; Yan Y; Lee H; Koppula P; Wu S; Zhuang L; Fang B; Poyurovsky MV; Olszewski K; Gan B
Nature; 2021 May; 593(7860):586-590. PubMed ID: 33981038
[TBL] [Abstract][Full Text] [Related]
19. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Pastor Fernández A; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson AL; Johansson L; Färnegårdh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Håkansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Laín S
Nat Commun; 2018 Mar; 9(1):1107. PubMed ID: 29549331
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
